Hwail Pharmaceutical Overview

  • Year Founded
  • 1974

Year Founded

  • Status
  • Public

  • Employees
  • 161

Employees

  • Stock Symbol
  • 061250

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $4.08
  • (As of Friday Closing)

Hwail Pharmaceutical General Information

Description

Hwail Pharm Co Ltd is engaged in manufacturing and distribution of raw materials used in pharmaceutical production. Its products include antitussive expectorants, spasmolytic, stomach function modifier, anti-inflammatory, and others.

Contact Information

Website
www.hwail.com
Formerly Known As
Jeil Pharmaceutical
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 241, Sandan-ro
  • Pyeongtaek, Gyeonggi
  • South Korea
+82
Primary Industry
Other Pharmaceuticals and Biotechnology
Stock Exchange
KRX
Corporate Office
  • 241, Sandan-ro
  • Pyeongtaek, Gyeonggi
  • South Korea
+82

Hwail Pharmaceutical Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hwail Pharmaceutical Stock Performance

As of 13-Nov-2026, Hwail Pharmaceutical’s stock price is $4.08. Its current market cap is $34.4M with 8.41M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.08 $4.04 $3.67 - $8.47 $34.4M 8.41M 24.7K $0.08

Hwail Pharmaceutical Financials Summary

As of 31-Mar-2026, Hwail Pharmaceutical has a trailing 12-month revenue of $66.1M.

In Thousands,
USD
TTM 31-Mar-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,815 13,566 28,508 63,595
Revenue 66,118 70,842 87,775 93,725
EBITDA 802 239 5,769 3,349
Net Income 704 (164) 4,750 2,955
Total Assets 141,533 148,027 146,377 144,335
Total Debt 233 233 2,280 1,815
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hwail Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hwail Pharmaceutical‘s full profile, request access.

Request a free trial

Hwail Pharmaceutical Patents

Hwail Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025263998-A1 Novel salt of tegoprazan and method for preparing same Pending 20-Jun-2024
WO-2015080435-A1 Method for preparing 4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide Inactive 26-Nov-2013
EP-2398450-A2 Aqueous nanoemulsion composition containing conjugated linoleic acid Active 20-Feb-2009
EP-2398450-A4 Aqueous nanoemulsion composition containing conjugated linoleic acid Active 20-Feb-2009
EP-2398450-B1 Aqueous nanoemulsion composition containing conjugated linoleic acid Active 20-Feb-2009 A61K8/06
To view Hwail Pharmaceutical’s complete patent history, request access »

Hwail Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hwail Pharmaceutical Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hwail Pharmaceutical‘s full profile, request access.

Request a free trial

Hwail Pharmaceutical Investments & Acquisitions (5)

Hwail Pharmaceutical’s most recent deal was a Corporate Asset Purchase with Ecovolt (Land and Buildings at 241 Sandan-ro in Pyeongtaek, South Korea) for . The deal was made on 06-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Ecovolt (Land and Buildings at 241 Sandan-ro in Pyeongtaek, South Korea) 06-Dec-2024 Corporate Asset Purchase Buildings and Property
Dynamic solution (Therapeutic Devices) 09-Apr-2024 PIPE Therapeutic Devices
PanGen Biotech 27-Mar-2024 PIPE Pharmaceuticals
CTCBio 01-Apr-2021 PIPE Pharmaceuticals
HuonsLifeSciences 07-Dec-2015 Merger/Acquisition Pharmaceuticals
To view Hwail Pharmaceutical’s complete investments and acquisitions history, request access »

Hwail Pharmaceutical ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Hwail Pharmaceutical’s complete esg history, request access »

Hwail Pharmaceutical Exits (1)

Hwail Pharmaceutical’s most recent exit was on 07-Dec-2015 from HuonsLifeSciences. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
HuonsLifeSciences 07-Dec-2015 Completed
  • 2 buyers
To view Hwail Pharmaceutical’s complete exits history, request access »

Hwail Pharmaceutical FAQs

  • When was Hwail Pharmaceutical founded?

    Hwail Pharmaceutical was founded in 1974.

  • Where is Hwail Pharmaceutical headquartered?

    Hwail Pharmaceutical is headquartered in Pyeongtaek, South Korea.

  • What is the size of Hwail Pharmaceutical?

    Hwail Pharmaceutical has 161 total employees.

  • What industry is Hwail Pharmaceutical in?

    Hwail Pharmaceutical’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Hwail Pharmaceutical a private or public company?

    Hwail Pharmaceutical is a Public company.

  • What is Hwail Pharmaceutical’s stock symbol?

    The ticker symbol for Hwail Pharmaceutical is 061250.

  • What is the current stock price of Hwail Pharmaceutical?

    As of 13-Nov-2026 the stock price of Hwail Pharmaceutical is $4.08.

  • What is the current market cap of Hwail Pharmaceutical?

    The current market capitalization of Hwail Pharmaceutical is $34.4M.

  • What is Hwail Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Hwail Pharmaceutical is $66.1M.

  • What is Hwail Pharmaceutical’s annual earnings per share (EPS)?

    Hwail Pharmaceutical’s EPS for 12 months was $0.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process